ARROWHEAD PHARMACEUTICALS, INC. State and Local Income Tax Expense (Benefit), Continuing Operations
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported State and Local Income Tax Expense (Benefit), Continuing Operations of $304.00 thousand for the 12-month period ending 2022-09-30, per its 10-K filed 2022-11-28.
Discontinued › Expense Statement › Income Tax
us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2022-11-28
- ARROWHEAD PHARMACEUTICALS, INC. state and local income tax expense (benefit), continuing operations for fiscal 2022 was $304.00K, a 15100.00% increase from fiscal 2021.
- ARROWHEAD PHARMACEUTICALS, INC. state and local income tax expense (benefit), continuing operations for fiscal 2021 was $2.00K, a 0.00% change from fiscal 2020.
- ARROWHEAD PHARMACEUTICALS, INC. state and local income tax expense (benefit), continuing operations for fiscal 2020 was $2.00K, a 98.85% decline from fiscal 2019.
- ARROWHEAD PHARMACEUTICALS, INC. state and local income tax expense (benefit), continuing operations for fiscal 2019 was $173.55K, a 7131.38% increase from fiscal 2018.
| Period end | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2022-09-30 | $304.00K 10-K · filed 2022-11-28 | |
| 2021-09-30 | $2.00K 10-K · filed 2022-11-28 | |
| 2020-09-30 | $2.00K 10-K · filed 2021-11-22 | $2.40K 10-K · filed 2020-11-23 |
| 2019-09-30 | $173.55K 10-K · filed 2020-11-23 | |
| 2018-09-30 | $2.40K 10-K · filed 2019-11-25 | |
| 2017-09-30 | $2.40K 10-K · filed 2018-12-11 | |
| 2016-09-30 | $2.40K 10-K · filed 2017-12-12 | |
| 2015-09-30 | $2.40K 10-K · filed 2016-12-14 | |
| 2014-09-30 | $5.30K 10-K · filed 2015-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |